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Although the urinary tract is constantly challenged by
microbial invasion, it remains free from colonization.
Although little is known about how the urinary tract
maintains sterility, the presence of antimicrobial peptides
(AMPs) in the urine suggests that they may play a role in
its protection from infection. Ribonuclease 7 (RNase 7) is a
potent AMP that was first identified in the skin. Here, we
characterize the expression and relevance of RNase 7 in the
human kidney and urinary tract. Using RNA isolated
from healthy human tissue, we performed quantitative
real-time PCR and found basal RNASE7 expression in
kidney and bladder tissue. Immunohistochemical and
immunofluorescent analysis localized RNase 7 to the
urothelium of the bladder, ureter, and the intercalated cells
of the collecting tubules. In control urine samples from
healthy individuals, the concentration of RNase 7 was found
to be in the low micromolar range; very abundant for an
AMP. Antibacterial neutralization assays showed that urinary
RNase 7 has potent antimicrobial properties against
Gram-negative and Gram-positive uropathogenic bacteria.
Thus, RNase 7 is expressed in the human kidney and urinary
tract and it may have an important antimicrobial role in
maintaining tract sterility.
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The urinary tract, except for the urethral meatus, is usually
sterile despite its proximity with fecal flora. The precise
mechanism by which the urinary tract maintains sterility is
not well understood.1 Recently, antimicrobial peptides
(AMPs) have been shown to have an important role in
innate immunity.2 AMPs are a ubiquitous component of
innate immunity produced by epithelial cells or hemato-
poietic cells. AMPs are mainly cationic proteins that possess
antimicrobial activity against bacteria, enveloped viruses,
fungi, and some protozoa. They may be constitutively
expressed and/or induced by invading pathogens.3–5
Although many AMPs have been described in other organ
systems, only a few AMPs have been studied in the human
urinary tract.5 In this study, we describe the expression and
function of ribonuclease 7 (RNase 7), a novel AMP in human
kidney tissue and the urinary tract.
Harder and Schro¨der6 first identified RNase 7 as an
abundant protein in the human epidermis while examining
protein extracts of normal skin for antimicrobial activity.
Subsequent studies demonstrated that RNASE 7 is expressed
in other organs, including the liver, gastrointestinal tract,
heart, skeletal muscle, and respiratory tract. RNASE 7
expression was noted in the kidney, although the extent of
its expression and precise location were not characterized.6,7
Although the mechanisms for the antimicrobial properties of
RNase 7 are not completely understood, its bactericidal
activity has been linked to its capacity to permeate
and disrupt the bacterial membrane, independent of its
ribonuclease activity.4,7–12 Consequently, RNase 7 has potent
antimicrobial activity against Gram-negative bacteria,
Gram-positive positive bacteria, and yeast.6,13–16 It has
been stated that, on a per molar base, RNase 7 is one
of the most potent human AMPs that has been described,
with antibiotic concentrations ranging in the low micromolar
range.4
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RESULTS
Human kidney and bladder tissue express high levels of
RNASE7 mRNA
In the bladder, mean RNASE7 expression was 117,530±1880
transcripts per 10 ng RNA. RNASE7 expression was signifi-
cantly greater in the bladder than within the kidney
(P¼ 0.0003). In the kidney, RNASE7 expression was analyzed
separately in the cortex, medulla, and pelvis. All tissue
sections tested expressed RNASE7 (Figure 1). RNASE7
expression was greatest in the renal pelvis compared with
other parts of the kidney, with a mean RNASE7 expression of
1395±65 transcripts per 10 ng RNA. RNASE7 expression was
significantly greater in the renal pelvis than the renal cortex
and medulla (P¼ 0.0015).
RNase 7 is expressed throughout the human kidney and
urinary tract
To investigate the distribution of RNase 7 in healthy human
kidney, ureter, and bladder tissue, we performed immuno-
histochemistry (IHC) and immunofluorescence using anti-
bodies directed against RNase 7. RNase 7 immunoreactivity
was present throughout the urothelium of the ureter and
bladder of all investigated specimens (n¼ 4; Figure 2). RNase
7 was also expressed in the renal cortex and renal medulla of
all specimens (Figure 3). RNase 7 showed cell-specific
expression in the cortical and medullary collecting tubules.
The glomeruli, proximal tubules, and loops of Henle did not
show RNase 7 staining. Negative controls showed no RNase 7
immunoreactivity (Figures 2 and 3).
RNase 7 is expressed in a specific subset of cells in the human
collecting tubule
Expression of RNase 7 in individual cell types of the
collecting tubule was performed using markers for principal
cells (aquaporin-2), a-intercalated cells (anion exchanger-1
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Figure 1 |Abundant expression of ribonuclease 7 (RNASE 7) in
human kidney and bladder. Transcript levels quantified by real-
time PCR in the kidney and bladder. Shown are the results of three
independent samples. On the line below, the mean transcript
levels are shown with the s.e.m. RNASE 7 expression was
significantly greater in the bladder than the kidney (cortex,
medulla, and pelvis; P¼ 0.003). RNASE 7 expression was
significantly greater in the renal pelvis than the cortex and
medulla (P¼ 0.0015).
Figure 2 |Ribonuclease 7 (RNase 7) is expressed throughout
the urothelium of the ureter and bladder. Immunohisto-
chemistry (IHC) demonstrates RNase 7 expression (brown/arrows)
throughout the urothelium of the (a) human bladder and
(c) ureter. Negative control (b) bladder and (d) ureter. Original
magnification  40.
Figure 3 |Ribonuclease 7 (RNase7) shows cell-specific expres-
sion throughout the human kidney. Immunohistochemistry
demonstrates isolated cell-specific expression (arrows) in the
collecting tubule of (a) human kidney cortex and (c) medulla.
Negative control (b) cortex and (d) medulla. Original
magnification  20.
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(AE-1)), and b-intercalated cells (pendrin) (Figure 4 and
Supplementary Figure S1 online). The a- and b-intercalated
cells expressed RNase 7, but principal cells did not. Occa-
sionally, pendrin-positive and AE-1-positive cells did not
demonstrate RNase 7 expression. Negative controls showed
no RNase 7 expression.
RNase 7 exists in human urine in measurable titers
Immunoblot analysis of cationic RNase 7 protein extracted
from urine specimens identified an immunoreactive peptide
that migrated to 14.5 kDa (data not shown).6 Enzyme-linked
immunosorbent assay (ELISA) demonstrated that RNase 7,
normalized to urine creatinine, was present in all urine
samples with concentrations ranging from 5.60 to 20.0±
0.92 mg/mg Cr (235–3467.2 mg/l), which corresponds to
0.17–0.3 mmol/l (Figure 5).
RNase 7 displays antibacterial properties in human urine
To determine if RNase 7 has antibacterial effects in human
urine, we inoculated urine samples from healthy individuals
with either uropathogenic Escherichia coli, Pseudomonas,
Enterococcus, Klebsiella, or Proteus mirabilis (Figure 6 and
Supplementary Figure S2 online). Next, we analyzed whether
the addition of antibodies directed against RNase 7 would
neutralize the antimicrobial activity of RNase 7 and lead to
enhanced bacterial growth. RNase 7 antibodies inhibited the
action of RNase 7 as bacterial growth of Gram-negative
bacteria and Proteus significantly increased (Figure 6 and
Supplementary Figure S2 online). The presence of equivalent
concentrations of irrelevant antibodies (derived from goat
pre-immune serum) had no effect on bacterial growth.
Because the pH of human urine is highly variable, we used
this approach to determine the effective pH range for the
antimicrobial effects of RNase 7 in urine. Urine samples from
healthy individuals were buffered to pH 5.0, 7.0, or 9.0.
Bacterial growth was monitored (optical density (OD) 600nm)
in the presence or absence of antibodies directed against RNase
7. We observed significant bacterial growth at all pH values
tested, although growth was impeded in alkaline conditions
(Figure 6 and Supplementary Figure S2 online). Enterococcus
demonstrated very little growth under all conditions (Supple-
mentary Figure S2 online). These results are consistent with
previous reports on the influence of pH on bacterial growth.17
The application of antibodies directed against RNase 7
resulted in increased bacterial growth under most urinary pH
values tested. However, this phenomenon was not uniform
under all conditions (Figure 6 and Supplementary Figure S2
online).
DISCUSSION
Previous studies have demonstrated that RNase 7 is an
important AMP in skin, hair follicles, and the oral
cavity.6,16,18,19 In this study, we demonstrate that RNase 7 is
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Figure 4 |Cell-specific expression of ribonuclease 7 (RNase 7) in the renal collecting tubule. Human kidney was labeled for RNase 7
(green), nuclei (blue), and cell type markers (red). Cell type markers consisted of aquaporin-2 (AQP-2) for principal cells, anion exchanger-1
(AE-1) for a-intercalated cells, and pendrin for b-intercalated cells. Isolated cells positive for RNase7 were identified in the collecting tubule.
(a) Principal cells (apical red staining) were negative for RNase 7 (green). (b) RNase 7 (green) was expressed by a-intercalated cells (red
basolateral AE-1 staining). (c) RNase 7 (green) and pendrin (red) colocalized in b-intercalated cells to demonstrate apical yellow staining
(arrow). Original magnification  100.
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Figure 5 |Ribonuclease 7 (RNase 7) is present in urine. Urinary
RNase 7 expression standardized to urine creatinine. Shown are
the enzyme-linked immunosorbent assay (ELISA) results from
20 healthy controls.
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a novel AMP expressed in the human urinary tract. Our
results demonstrate that RNase 7 is constitutively expressed
in the mature human kidney, ureter, and bladder. Using
quantitative real-time PCR and ELISA, we demonstrate that
RNase 7 activity is greatest in the bladder and renal medulla.
Specifically, immunohistochemical labeling demonstrates
that RNase 7 is expressed throughout the urothelium of the
lower urinary tract and the intercalated cells of the collecting
tubules. These results suggest that intercalated cells have a
novel role in innate immunity. Finally, we identify high
concentrations of RNase 7 in the urine and demonstrate that
RNase 7 has urinary antimicrobial activity against a variety of
uropathogenic bacteria.
Our quantitative real-time PCR results demonstrate that
RNASE7 is expressed at high levels throughout the urinary
tract. The basal uroepithelial expression of RNASE7 is greater
than the expression of previously described urinary tract
AMPs like cathelicidin, human b-defensin 1 (hBD-1), and
hBD-2.20–23 Furthermore, our results indicate that renal
RNASE7 expression is comparable with RNASE7 expression
in keratinocytes.16 When comparing RNASE7 expression in
the bladder with RNASE7 expression in the skin, our results
demonstrate that the bladder expresses nearly 100 times more
RNASE7 than primary keratinocytes.16 High expression levels
may be required in the bladder to produce bactericidal titers
of RNase 7 because it is constantly excreted into and/or
diluted by urine.
Our quantitative real-time PCR results also demonstrate
that RNASE7 expression increased from the upper urinary
tract to the lower urinary tract—following the flow of the
urinary stream. Similarly, immunostaining demonstrated
that RNase 7 expression is more homogeneous throughout
the lower urinary tract. IHC demonstrated cell-specific
RNase 7 expression in a minority of isolated cells in the
cortical and medullary collecting tubules before becoming
more uniform throughout the uroepithelium of the ureter
and bladder. RNase 7 was not expressed in the glomeruli,
proximal tubules, loops of Henle, or interstitium. This
expression pattern differs from the expression of other AMPs
that have been described in the kidney. For example, hBD-1,
hBD-2, and cathelicidin do not show cell-specific expression,
and they have limited or no intracellular expression.20–22,24,25
Because RNase 7 protein expression is limited to a
minority of cells in the renal cortex and medulla, only a
small percentage of cells account for the relatively high
RNASE7 expression levels, especially when compared with
more homogenous epithelial organs like the epidermis.
Overall, both real-time PCR and IHC indicate that RNase 7
expression is present in locations where microbial exposure
occurs most frequently. A similar expression pattern has been
described in the epidermis and in hair follicles. In the skin,
RNase 7 expression is greatest in the uppermost epidermal
layers, where microbial insult most likely occurs. Likewise, in
hair follicles RNase 7 expression is greatest in the outer root
sheath.14,19
Our results indicate that a- and b-intercalated cells
constitutively express RNase 7. Historically, intercalated cells
have been shown to play important roles in the regulation of
acid/base homeostasis. Intercalated cells account for one-
third of the cells within the cortical and medullary collecting
tubules.26–28 Given their physiological position in the
collecting tubule, intercalated cells are ideally positioned to
defend the kidney from ascending urinary tract infections
(UTIs) as they are one of the initial cell types encountered by
ascending microbes before they infiltrate the renal parench-
yma. The identification of RNase 7 in both subtypes of
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Figure 6 |Ribonuclease 7 (RNase 7) contributes to impaired growth of Escherichia coli and Pseudomonas in human urine. The
antibacterial properties of RNase 7 were measured as changes in the turbidity of cultured human urine using the absorbance at 600 nm
(OD600). Human urine samples were inoculated at various urinary pH conditions with (a–c) E. coli or (d–f) Pseudomonas as shown by the solid
black line. The open circles represent noninoculated urine samples. Addition of irrelevant antibody to inoculated urine samples (dashed
line) did not affect bacterial growth. Blocking of RNase 7 activity, with the addition of RNase 7 antibody (dashed line with diamonds),
resulted in increased growth of all bacterial isolates.
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intercalated cells defines a new role for these cells, indicating
that they are critical for the production and secretion of
AMPs into the urine.
Our ELISA results indicate that RNase 7 is secreted into
the urine. Given the size of RNase 7 (14.5 kDa), it is possible
that some urinary RNase 7 peptides originate, at least in part,
from plasma filtrate. However, there is little evidence
suggesting that RNase 7 persists in the plasma.7 Additionally,
to persist in the urine, RNase 7 would need to escape the
efficient peptide absorption mechanisms in the proximal
tubule.29,30 Finally, the urine samples underwent centrifuga-
tion before processes, removing cellular sources of RNase 7.
This finding suggests that the predominant source of urinary
RNase 7 most likely originates from local production by
intercalated cells of the distal nephron and the urothelium of
the bladder and ureters.
In our study of 20 healthy individuals, constitutive
urinary RNase 7 protein concentration was between 5.6 and
20.0 mg/mg Cr (0.17–0.3 mmol/l). When comparing urinary
RNase 7 concentrations with the concentrations of other
urinary AMPs (that is, cathelicidin, hBD-1, and hBD-2),
RNase 7 concentrations are much greater. hBD-2 is not
constitutively secreted in the urine, whereas median urinary
concentrations of cathelicidin and hBD-1 are 1.6 105 and
2.5 105 mmol/l, respectively.20,21,23,25 Constitutive RNase 7
expression at these concentrations shows potent antimicro-
bial activity against several pathogenic microbes, including
Pseudomonas aeruginosa, Staphylococcus aureus, and vanco-
mycin-resistant Enterococcus faecium.6,15,31,32
As observed in other systems, RNase 7 demonstrates
antimicrobial activity in the urine. When the antimicrobial
activity of RNase 7 was inhibited with antibodies directed
against RNase 7, bacterial growth of E. coli, Pseudomonas,
Klebsiella, and Proteus significantly increased. This effect was
observed at all urinary pH values, but was less pronounced
under alkaline urine conditions. This phenomenon may be
secondary to decreased activity of RNase 7 at a higher pH, or
it may reflect differential expression of microbial proteins
that are important for RNase 7 antimicrobial activity. The
effect of urine pH on RNase 7 activity and bacterial gene
expression are currently under investigation. Overall, these
data suggest that RNase 7 is involved in maintaining urine
sterility, which is consistent with the proposed role of RNase
7 in innate immunity and antimicrobial defense.4,13,16
In conclusion, this is the first study to identify and
evaluate RNase 7 in the human kidney and urinary tract. Our
results suggest that RNase 7 is an epithelial-derived AMP that
plays an important role in the innate immunity of the human
uroepithelium. We demonstrate that RNase 7 contributes to
host defense against Gram-negative and Gram-positive
bacteria. Because RNase 7 production occurs in intercalated
cells of the distal nephron, we believe these cells are
important in the production of AMPs. Further evaluation
of human epithelial AMPs, like RNase 7, may lead to the
development of new treatment strategies for antibiotic-
resistant UTIs.
MATERIALS AND METHODS
Study approval
The Nationwide Children’s Hospital (NCH) institutional review
board approved this study (IRB-07-00383). Uropathogen bacterial
isolates were obtained from patients seeking treatment for UTIs at
NCH as approved by the institutional review board (IRB-06-00603).
Human tissue and urine samples
Human kidney and ureter tissue was obtained through the NCH
Department of Pathology. Tissue samples were obtained from
pediatric patients undergoing nephrectomy for Wilm’s tumor.
Tissue samples were free of microscopic signs of disease or
inflammation. The tissue was preserved as neutral formalin-fixed
paraffin-embedded sections and dissected into cortex, medulla, or
renal pelvis before storage. Human bladder uroepithelium, snap
frozen in liquid nitrogen, was obtained from children undergoing
ureteral re-implantation for reasons other than recurrent infection.
Three bladder tissue specimens were obtained.
Urines samples (n¼ 20) were obtained from healthy volunteers
with no history of UTI. The urine samples were centrifuged to
remove urine sediment and protease inhibitor cocktail was added
(Thermo Scientific, Rockford, IL).
Ribonucleic acid isolation and reverse transcription
Total RNA was isolated from frozen tissue using the Promega Total
RNA Isolation System (Promega, Madison, WI). For cDNA
synthesis, 4–8 mg of total RNA was reverse transcribed with
Superscript III reverse transcriptase using an oligo-(dT)1218 primer
according to the supplier’s protocol (Invitrogen, Carlsbad, CA). A
single cDNA preparation from each specimen was used for the assay
of all antimicrobial products tested.
Cloning of gene-specific plasmids for standard curves
The cDNAs encoding RNase7 and GAPDH (glyceraldehyde
3-phosphate dehydrogenase) were cloned into a 4-Topo plasmid
vector (Invitrogen) according to the manufacturer’s instructions.
Plasmids were sequenced to confirm that the correct constructs were
obtained. Serial dilutions of gene-specific plasmids were quantitated
(by both spectrophotometric absorbance at 260 nm and ethidium
bromide staining agarose gel electrophoresis with DNA standards)
and then used in real-time PCR to generate standard curves for each
reaction.
Real-time PCR
Total cellular RNA was extracted from the collected specimens using
SV Total RNA Isolation System (Promega) according to the
manufacturer’s protocol. Real-time PCR was performed using
single-stranded cDNA from human kidney and bladder tissue with
specific oligonucleotide primer pairs using the 7500 Real-Time PCR
System (Applied Biosystems, Carlsbad, CA) equipped with a
fluorescence detection monitor. PCR intron spanning primers were
selected using previously published standards and sequences were
confirmed using DNAstar Laser Gene SeqBuilder (RNase 7 forward
primer: 50-GGAGTCACAGCACGAAGACCA-30 and RNase 7 reverse
primer 50-CATGGCTGAGTTGCATGCTTGA-30).16
Briefly, cDNA corresponding to 10 ng RNA served as a template
in a 25 ml reaction containing 75 nmol/l of each primer, and 1
Light-Cycler-Fast Start DNA Master SYBR Green mix. The PCR
conditions were: initial denaturation at 95 1C for 10min, followed
by 40 cycles with each cycle consisting of denaturation at 94 1C for
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30 s, annealing at 62 1C for 30 s, and extension at 72 1C for 30 s. The
cycle-to-cycle fluorescence emission was monitored at 530 nm and
analyzed using 7500 Software V2.0.3 (Applied Biosystems). Gene-
specific plasmid standards were included with every set of reactions.
Absolute transcript levels are shown per 10 ng total RNA.
RNase 7 antibodies
Antibodies against RNase 7 were commercially purchased (Abcam,
Cambridge, MA; Novus Biologicals, Littleton, CO; and Sigma-
Aldrich, St Louis, MO). According to the manufacturer, the Novus
and Sigma antibodies do not crossreact with other proteins. The
Abcam antibody does have some crossreactivity between RNase 7
and RNase 8. However, previous studies indicate that human RNase
8 expression is limited to the placenta and absent in the kidney.33
ELISA
Flat-bottomed, 96-well plates (Maxisorb, Nunc, Rochester, NY) were
coated overnight at 4 1C with polyclonal antibody to RNase7 (3mg/ml;
Abcam). After blocking with synthetic blocking buffer (Kem-En-Tec
Diagnostics, Taastrup, Denmark) for 2 h at room temperature,
standards and samples were added to the wells and incubated for
2 h at room temperature. Serial dilutions of recombinant RNase 7
protein served as the standards (Novus Biologicals). Following
incubation with a different biotinylated (Lightning-Link Biotin
Antibody Labeling Kit, Novus Biologicals) polyclonal antibody to
RNase7 (2mg/ml; Novus Biologicals) for 2 h at room temperature,
streptavidin-horseradish peroxidase (Biolegend, San Diego, CA) was
added for 30min. After incubation with TMB substrate solution for
15min (Kem-En-Tec Diagnostics), the reaction was terminated with
STOP solution (Cell Signaling Technology, Danvers, MA) and read at a
wavelength of 450 nm and with 570-nm background subtraction. The
detection limit of the ELISA was 0.1ng/ml.
Results from the ELISA assay were divided by urine creatinine to
establish standardized urine RNase 7-to-creatinine ratios (mg/mg) to
account for urine dilution. Urine creatinine concentrations were
determined using the Oxford Biomedical Research creatinine
microplate assay (Rochester Hills, MI).
Immunoblot analysis
Urinary proteins were extracted from human urine samples using the
Proteospin Urine Protein Concentration Micro Kit according to the
manufacturer’s instructions (Norgen Biotek Corporation, Thorold, ON,
Canada). The urine protein samples were mixed with Laemmli sample
buffer and incubated at 95 1C for 5min. The samples were loaded onto
18% sodium dodecyl sulfate gradient gels and subjected to electropho-
resis (applied constant voltage of 100V). After the peptide/protein
separation, the material in the gel was transferred to nitrocellulose by
application of 100V for 90min. The membranes were blocked in 2% fat-
free milk and incubated with the rabbit polyclonal RNase 7 antibody
(Abcam) in phosphate-buffered saline with 2% fat-free milk overnight at
4 1C. This was followed by incubation with the secondary antibody, a
monkey horseradish peroxidase-conjugated anti-rabbit IgG diluted
1:8000 in phosphate-buffered saline with 5% fat-free milk, for 1h at
room temperature. The proteins and peptides were visualized using an
ECL detection system and chemiluminescence film according to the
manufacturer’s instructions (BioExpress, Kaysville, UT).
Immunohistochemistry
IHC was performed on human kidney specimens to evaluate RNase
7 expression at the cellular level. Following deparaffinization and
rehydration, antigen retrieval was performed in a pressure cooker
for 20min using 0.01mol/l citrate buffer (pH 6.0). This step
was followed by a biotin block and a serum-free protein block
(Superblock, ScyTek Laboratories, Logan, UT). The slides were
incubated overnight at 4 1C with polyclonal rabbit RNase 7 antibody
(Sigma-Aldrich) diluted 1:50 in phosphate-buffered saline contain-
ing 3% fetal bovine serum followed by anti-polyvalent biotinylated
antibody (anti-mouse, rat, rabbit, guinea pig) and UltraTek
Streptavidin/HRP (ScyTek Laboratories).
Sections were developed using 0.1% diaminobenzidine tetra-
chloride (Arcos Organics, Geel, Belgium) with 0.02% hydrogen
peroxide and counterstained with hematoxylin. Negative controls
sections were incubated with nonimmune serum in place of RNase7
antibody.
Immunofluorescence
Double-labeled immunofluorescence was performed to help localize
RNase 7 expression in the kidney. Sections were double labeled for
principal cells with goat polyclonal anti-human aquaporin-2
antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Sections were double labeled for intercalated cells with mouse IgG1
monoclonal anti-human AE-1 antibody (gift from M Jennings) or
mouse IgG1 monoclonal anti-human pendrin antibody (Medical and
Biological Laboratories, Naka-ku Nagoya, Japan). The a-intercalated
cells show basolateral AE-1 expression and b-intercalated cells show
apical pendrin expression.28 Rhodamine donkey polyclonal anti-goat
(Jackson ImmunoResearch Laboratories, West Grove, PA), rhodamine
goat anti-mouse (Jackson ImmunoResearch Laboratories), and
fluorescein isothiocyanate donkey polyclonal anti-rabbit (Santa Cruz)
served as the secondary antibodies.
All sections were prepared as outlined above. They were
incubated with a mixture of antisera against RNase 7 (1:50;
Sigma-Aldrich) and antisera against AE-1 (1:50), pendrin (1:50),
or aquaporin-2 (1:200) at room temperature for 90min. The secon-
dary antibody was applied for 1 h at room temperature and the
sections were mounted using mounting media with 4,6-diamidino-
2-phenylindole. Nonimmune serum was used as a negative control.
The slides were examined with a Leica DM4000B microscope
(Wetzlar, Germany) and digitally photographed using the  100
objective and Spot RT camera/software (Diagnostic Instruments,
Sterling Heights, MI). The final images were processed with Adobe
Photoshop software (Adobe Systems, San Jose, CA).
Antimicrobial neutralization assay
RNase 7 antimicrobial activity against uropathogenic E. coli
(UTI-89), P. aeruginosa (PEDUTI-61), Enterococcus (PEDUTI-39),
Klebsiella (PEDUTI-65), and Proteus mirabilis (PEDUTI-44) was
evaluated in human urine. These bacterial strains were isolated from
positive urine cultures of patients at NCH. In brief, the bacteria were
cultured at 37 1C overnight in Luria-Bertani broth to saturation.
Bacteria (1 ml) was added to 100 ml a healthy individual in a 96-well
flat bottom plate (Thermo Scientific, Nunc, Worcester, MA). To
each well, 10 mg of anti-RNase 7 antibody (Novus) or equivalent
concentrations of irrelevant antibody (derived from preimmune
goat serum) were added.16
Bacterial growth was monitored using a Synergy HTmulti-mode
microplate reader (BioTek Instruments, Winooski, VT) at a final
volume of 101 ml. The turbidity of the culture was measured and
recorded at t¼ 0 and every 10min thereafter for 10 h using the
absorbance at 600 nm (OD600). Sterility of urine was validated by
incubation in the absence of bacterial inoculation. The assays were
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performed at a urinary pH of 5.0, 7.0, and 9.0. The urinary pH was
adjusted by the titration of 0.1N hydrochloric acid or sodium
hydroxide.
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